English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors

Ancker, O. V., Wehland, M., Bauer, J., Infanger, M., & Grimm, D. (2017). The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors. International Journal of Molecular Sciences, 18(3): 625. doi:10.3390/ijms18030625.

Item is

Files

show Files
hide Files
:
ijms-18-00625.pdf (Publisher version), 2MB
Name:
ijms-18-00625.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
License:
-

Locators

show

Creators

show
hide
 Creators:
Ancker, Ole Vincent1, Author
Wehland, Markus1, Author
Bauer, Johann2, Author              
Infanger, Manfred1, Author
Grimm, Daniela1, Author
Affiliations:
1external, ou_persistent22              
2Scientific Service Groups, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565170              

Content

show
hide
Free keywords: ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; BETA-ADRENOCEPTOR ANTAGONISTS; NITRIC-OXIDE DONORS; ANGIOGENESIS INHIBITORS; HEART-FAILURE; DOUBLE-BLIND; SORAFENIB; SUNITINIB; LENVATINIBBiochemistry & Molecular Biology; Chemistry; thyroid cancer; hypertension; vascular endothelial growth factor; multi-kinase inhibitors; lenvatinib; sorafenib; sunitinib;
 Abstract: The treatment of thyroid cancer has promising prospects, mostly through the use of surgical or radioactive iodine therapy. However, some thyroid cancers, such as progressive radioactive iodine-refractory differentiated thyroid carcinoma, are not remediable with conventional types of treatment. In these cases, a treatment regimen with multi-kinase inhibitors is advisable. Unfortunately, clinical trials have shown a large number of patients, treated with multi-kinase inhibitors, being adversely affected by hypertension. This means that treatment of thyroid cancer with multi-kinase inhibitors prolongs progression-free and overall survival of patients, but a large number of patients experience hypertension as an adverse effect of the treatment. Whether the prolonged lifetime is sufficient to develop sequelae from hypertension is unclear, but late-stage cancer patients often have additional diseases, which can be complicated by the presence of hypertension. Since the exact mechanisms of the rise of hypertension in these patients are still unknown, the only available strategy is treating the symptoms. More studies determining the pathogenesis of hypertension as a side effect to cancer treatment as well as outcomes of dose management of cancer drugs are necessary to improve future therapy options for hypertension as an adverse effect to cancer therapy with multi-kinase inhibitors.

Details

show
hide
Language(s): eng - English
 Dates: 2017
 Publication Status: Published online
 Pages: 19
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000396253700154
DOI: 10.3390/ijms18030625
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: International Journal of Molecular Sciences
  Abbreviation : Int. J. Mol. Sci.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Basel, Switzerland : MDPI AG
Pages: - Volume / Issue: 18 (3) Sequence Number: 625 Start / End Page: - Identifier: ISSN: 1422-0067
CoNE: https://pure.mpg.de/cone/journals/resource/1422-0067